1921
Volume 99, Issue 2
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

Abstract.

We investigated the in vitro activity of a novel fifth-generation cephalosporin–tazobactam combination, ceftolozane–tazobactam against , the etiological agent of melioidosis. Using both disc diffusion and minimum inhibitory concentration (MIC) strip techniques against 56 clinical isolates and an national collection of type cultures (NCTC) strain, the MIC to ceftolozane–tazobactam was found to be between 0.75 and 4 mcg/mL. The MIC50 was found to be 1.5 mcg/mL and MIC90 was 2.0 mcg/mL. This study provides initial evidence of ceftolozane–tazobactam as a novel agent in the management of melioidosis.

Loading

Article metrics loading...

The graphs shown below represent data from March 2017
/content/journals/10.4269/ajtmh.17-0049
2018-06-25
2019-11-17
Loading full text...

Full text loading...

/deliver/fulltext/14761645/99/2/tpmd170049.html?itemId=/content/journals/10.4269/ajtmh.17-0049&mimeType=html&fmt=ahah

References

  1. Cheng AC, Currie BJ, , 2005. Melioidosis: epidemiology, pathophysiology, and management. Clin Microbiol Rev 18: 383416. [Google Scholar]
  2. White NJ, , 2003. Melioidosis. Lancet 361: 17151722. [Google Scholar]
  3. Schweizer HP, , 2012. Mechanisms of antibiotic resistance in Burkholderia pseudomallei: implications for treatment of melioidosis. Future Microbiol 7: 13891399. [Google Scholar]
  4. Cheng AC, , 2010. Melioidosis: advances in diagnosis and treatment. Curr Opin Infect Dis 23: 554559. [Google Scholar]
  5. Huntington JA, Sakoulas G, Umeh O, Cloutier DJ, Steenbergen JN, Bliss C, Goldstein EJ, , 2016. Efficacy of ceftolozane/tazobactam versus levofloxacin in the treatment of complicated urinary tract infections (cUTIs) caused by levofloxacin-resistant pathogens: results from the ASPECT-cUTI trial. J Antimicrob Chemother 71: 20142021. [Google Scholar]
  6. Solomkin J, 2015. Ceftolozane/tazobactam plus metronidazole for complicated intra-abdominal infections in an era of multidrug resistance: results from a randomized, double-blind, phase 3 trial (ASPECT-cIAI). Clin Infect Dis 60: 14621471. [Google Scholar]
  7. FDA, 2014. Prescribing Information—Ceftolozane/Tazobactam. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206829lbl.pdf. Accessed January 16, 2018.
  8. EUCAST, 2017. Addendum on Ceftolozane-Tazobactam Zone Diameter Breakpoints for Pseudomonas aeruginosa. Available at: http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_tables/Addenda/Addendum_June_2017_ceftolozane-tazobactam.pdf. Accessed August 28, 2017.
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.17-0049
Loading
/content/journals/10.4269/ajtmh.17-0049
Loading

Data & Media loading...

  • Received : 19 Jan 2017
  • Accepted : 26 Feb 2018
  • Published online : 25 Jun 2018

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error